Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H1, 2019

GlobalData's clinical trial report, “Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H1, 2019" provides an overview of Coronary Artery Disease (CAD) (Ischemic Heart Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Coronary Artery Disease (CAD) (Ischemic Heart Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Companies mentioned

AstraZeneca Plc

Abbott Laboratories

Eli Lilly and Co

Daiichi Sankyo Co Ltd

Merck & Co Inc

Boston Scientific Corp

Medtronic Plc

Pfizer Inc

Sanofi

Bayer AG

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

GlobalData Clinical Trials Report Coverage 7

Clinical Trials by Region 8

Clinical Trials and Average Enrollment by Country 9

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12

Top Five Countries Contributing to Clinical Trials in Europe 13

Top Countries Contributing to Clinical Trials in North America 14

Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15

Top Five Countries Contributing to Clinical Trials in Central and South America 16

Clinical Trials by G7 Countries: Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 17

Clinical Trials by Phase in G7 Countries 19

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 25

Clinical Trials by Phase 27

In Progress Trials by Phase 28

Clinical Trials by Trial Status 29

Clinical Trials by End Point Status 31

Subjects Recruited Over a Period of Time 32

Clinical Trials by Sponsor Type 33

Prominent Sponsors 34

Top Companies Participating in Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials 36

Prominent Drugs 38

Latest Clinical Trials News on Coronary Artery Disease (CAD) (Ischemic Heart Disease) 40

Apr 01, 2019: Resverlogix cognition substudy of the BETonMACE Phase 3 cardiovascular trial presented at the International Conference on Alzheimer’s & Parkinson’s Diseases 40

Mar 18, 2019: Bristol-Myers and Squibb-Pfizer report positive AUGUSTUS trial data 40

Mar 15, 2019: Some heart disease, A-fib patients On combined therapies could skip aspirin 40

Mar 13, 2019: Regeneron and Sanofi to present new Praluent (alirocumab) data at ACC.19 41

Mar 04, 2019: Cynata's Collaboration with University of New South Wales Yields Positive Preclinical Data for Coronary Artery Disease 42

Feb 25, 2019: AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients 42

Feb 11, 2019: Verseon presents PRecision Oral Anticoagulants (PROACs) with low bleeding at International Stroke Conference 2019 43

Feb 11, 2019: Verseon presents update on PRecision Oral Anticoagulant (PROAC) VE-2851 at International Stroke Conference 2019 43

Feb 05, 2019: Verseon starts dosing in trial of VE-1902 to treat CAD 44

Clinical Trial Profile Snapshots 45

Appendix 2059

Abbreviations 2059

Definitions 2059

Research Methodology 2060

Secondary Research 2060

About GlobalData 2061

Contact Us 2061

Source 2062

List of Tables

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region, 2019* 8

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 12

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 13

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries, 2019* 14

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 15

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 16

Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2019* 17

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2019* 22

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase, 2019* 27

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 28

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 33

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

List of Figures

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 11

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 12

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 13

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 14

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 15

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 16

Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, G7 Countries (%), 2019* 17

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 19

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 20

Proportion of Coronary Artery Disease (CAD) (Ischemic Heart Disease) to Cardiovascular Clinical Trials, E7 Countries (%), 2019* 22

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 24

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 25

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 27

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 28

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 29

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 31

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 32

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 33

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 34

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 36

Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 38

GlobalData Methodology 2060

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports